Table 2 Main characteristics of the studies included in an analysis of the XRCC1 Arg399Gln polymorphism and bladder cancer risk
From: Quantitative assessment of the associations between XRCC1 polymorphisms and bladder cancer risk
Study | Ethnicity | Country | Sample size (Frequency of A allele, %) | HWE in control | Quality score | Genotyping method | |
|---|---|---|---|---|---|---|---|
Case no | Control no | ||||||
Stern [19] | Caucasian | US | 235 (34.58) | 213 (36.55) | Yes | 8 | PCR-RFLP |
Shen [33] | Caucasian | Italy | 201 (32.09) | 214 (34.11) | Yes | 9 | PCR-RFLP |
Sanyal [34] | Caucasian | Sweden | 311 (35.21) | 246 (31.71) | Yes | 9 | PCR-RFLP |
Broberg [35] | Caucasian | Sweden | 61 (31.97) | 155 (28.39) | Yes | 9 | MALDI-TOF |
Wu [20] | Asian | China | 155 (27.74) | 155 (46.45) | Yes | 8 | PCR-RFLP |
Matullo [21] | Caucasian | Mixed | 131 (35.08) | 1,094 (33.73) | Yes | 11 | Taqman |
Wu [22] | Caucasian | US | 696 (34.01) | 629 (33.72) | Yes | 10 | Taqman |
Karahalil [36] | Caucasian | Turkey | 100 (32.00) | 100 (38.00) | Yes | 7 | PCR-RFLP |
Sak [24] | Caucasian | UK | 547 (35.71) | 579 (36.52) | Yes | 11 | Taqman |
Figueroa [25] | Caucasian | Spain | 1,150 (35.82) | 1,149 (33.79) | Yes | 11 | Taqman |
Andrew [26] | Caucasian | US, Italy | 1,029 (35.35) | 1,281 (36.07) | No | 10 | Taqman |
Hsu [27] | Asian | Taiwan | 221 (25.71) | 223 (25.46) | Yes | 8 | PCR-RFLP |
Arizono [37] | Asian | Japan | 251 (24.30) | 251 (26.29) | Yes | 8 | PCR-RFLP |
Fontana [28] | Caucasian | France | 51 (34.31) | 45 (40.00) | Yes | 5 | Taqman |
Wang [30] | Asian | China | 234 (32.26) | 253 (29.45) | Yes | 7 | PCR-RFLP |
Bianchino [31] | Caucasian | Italy | 32 (43.75) | 242 (30.99) | No | 4 | PCR-RFLP |
Mittal [32] | Asian | India | 212 (43.40) | 250 (37.40) | Yes | 9 | PCR-RFLP |
Zhi [38] | Asian | China | 302 (34.93) | 311 (29.42) | Yes | 10 | PCR-RFLP |